Pieris Pharmaceuticals will be laying off 70% of its workforce as part of a corporate restructuring following the termination of its...
9 months ago

Pieris (PIRS) soars as partner Boston Pharmaceuticals initiated early-stage study of PRS-342/BOS-342, triggering an undisclosed milestone...
3 days ago

Pieris Pharmaceuticals (NASDAQ:PIRS) has announced a reverse stock split of its common stock at a ratio of 1-for-80, set to take effect at...
2 weeks ago

Since it has a market capitalisation of US$21m, Pieris Pharmaceuticals' US$47m in cash burn equates to about 228% of its market value. That...
1 month ago

AstraZeneca has sailed away from a licensing deal for Pieris Pharmaceuticals' asthma med, forcing the biotech to begin charting a new...
9 months ago

Pieris Pharma leaps on news of restructuring ... Boston, USA-based clinical-stage biotech Pieris Pharmaceuticals (Nasdaq: PIRS) saw its shares...
9 months ago

Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary...
9 months ago

Shares of Pieris Pharmaceuticals (NASDAQ:PIRS), a biotech company focusing on innovative treatments for lung diseases and cancer, cratered today after...
10 months ago

It's clear to see that Pieris Pharmaceuticals maintains its low P/S on the weakness of its forecast for sliding revenue, as expected. As other...
4 months ago

Pieris Pharmaceuticals announced partner AstraZeneca's decision to discontinue clinical studies of elarekibep, an inhaled IL-4 receptor...
10 months ago